TOP - August 2015, Vol 8, No 3
Rolapitant 180 mg significantly reduced symptoms of chemotherapy-induced nausea and vomiting in patients treated with multiple cycles of highly or moderately emetogenic chemotherapy when compared with placebo in 4 double-blind, active-controlled studies. Read More ›
By Wayne Kuznar
The National Comprehensive Cancer Network (NCCN) now recommends nivolumab (Opdivo) as subsequent therapy for metastatic squamous non–small-cell lung cancer (NSCLC) after its recent FDA approval. Read More ›
By Chase Doyle
Although recent studies have shown the efficacy of using stereotactic body radiation therapy (SBRT) as a treatment modality for organ-confined prostate cancer, questions over urinary symptoms and sexual dysfunction have remained. Read More ›
- Abiraterone and Metabolic Syndrome
- Obesity and Survival in Metastatic Renal-Cell Carcinoma
- Radium-223 and Pain
- New Biomarker for Survival
- Quality of Life in Long-Term Survivors of Bladder Cancer
A successful pharmacist-driven drug-monitoring protocol can be achieved in a medical practice when necessary elements are considered. Read More ›
By Wayne Kuznar
A new clinical guideline for smoking cessation in patients with cancer encourages the use of evidence-based pharmacotherapy, behavioral therapy, and close follow-up with retreatment. Read More ›
The Academy of Oncology Nurse & Patient Navigators® (AONN+) is proud to announce that it has been granted membership in the American College of Surgeons Commission on Cancer (CoC). Read More ›
By Wayne Kuznar
In his NCCN update of the CLL guideline, Dr Wierda noted that the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica) could soon replace conventional chemotherapy. Read More ›
In this month’s issue of The Oncology Pharmacist, we present coverage of the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer. We highlight presentations on the effectiveness of rolapitant for chemotherapy-induced nausea and vomiting, as well as data on the association between osteonecrosis of the jaw and medication. Read More ›
With the exception of skin cancer, prostate cancer is the most common cancer affecting men. Read More ›